Cargando…

Pneumothorax in Patients with Pulmonary Langerhans Cell Histiocytosis

INTRODUCTION: Pneumothorax often develops in pulmonary Langerhans cell histiocytosis (PLCH), but some patients take a long time to be correctly diagnosed. OBJECTIVES: This study assessed the frequency of pneumothorax in PLCH and analysed the role of chest computed tomography (CT) in the prompt diagn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radzikowska, E., Błasińska–Przerwa, K., Wiatr, E., Bestry, I., Langfort, R., Roszkowski-Śliż, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Interstitial Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244644/ https://www.ncbi.nlm.nih.gov/pubmed/30187131 http://dx.doi.org/10.1007/s00408-018-0155-1

Ejemplares similares

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease
por: Tomioka, Hiromi, et al.
Publicado: (2016)

Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
por: Zhao, Yidan D, et al.
Publicado: (2017)

Neutrophil lymphocyte ratio as an indicator for disease progression in Idiopathic Pulmonary Fibrosis
por: Achaiah, Andrew, et al.
Publicado: (2022)

Physical Inactivity in Pulmonary Sarcoidosis
por: Cho, Peter S. P., et al.
Publicado: (2019)

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
por: McDonough, John E, et al.
Publicado: (2019)

Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI
por: Weatherley, Nicholas D, et al.
Publicado: (2021)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Relationship between body composition, exercise capacity and health-related quality of life in idiopathic pulmonary fibrosis
por: Machado, Felipe V C, et al.
Publicado: (2021)

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
por: Kraven, Luke M, et al.
Publicado: (2023)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials
por: Swigris, Jeffrey J, et al.
Publicado: (2018)

Central lung gene expression associates with myofibroblast features in idiopathic pulmonary fibrosis
por: Huang, Yong, et al.
Publicado: (2023)

Correlation of respiratory oscillometry with CT image analysis in a prospective cohort of idiopathic pulmonary fibrosis
por: Wu, Joyce K Y, et al.
Publicado: (2022)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts
por: Machahua, Carlos, et al.
Publicado: (2021)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis
por: Shapanis, Andrew, et al.
Publicado: (2023)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative
por: Kampstra, Nynke A, et al.
Publicado: (2019)

In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study
por: Durheim, Michael T., et al.
Publicado: (2019)

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations
por: Coghlan, Meghan A, et al.
Publicado: (2014)

Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis
por: Dutta, Prosenjit, et al.
Publicado: (2019)

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
por: Maher, Toby M, et al.
Publicado: (2019)

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services
por: Barratt, Shaney L, et al.
Publicado: (2021)

Acute exacerbation of idiopathic pulmonary fibrosis: a 10-year single-centre retrospective study
por: Yamazoe, Masatoshi, et al.
Publicado: (2018)

Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis
por: Kagiyama, Naho, et al.
Publicado: (2015)

Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
por: Jacob, Joseph, et al.
Publicado: (2020)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
por: Salonen, Johanna, et al.
Publicado: (2022)

Fine crackles on chest auscultation in the early diagnosis of idiopathic pulmonary fibrosis: a prospective cohort study
por: Moran-Mendoza, Onofre, et al.
Publicado: (2021)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Therapeutic effects of fatty acid binding protein 1 in mice with pulmonary fibrosis by regulating alveolar epithelial regeneration
por: Fu, Zhenli, et al.
Publicado: (2023)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis
por: Chandel, Abhimanyu, et al.
Publicado: (2023)

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2un4io94gof7uvf38vk8u9s8k4